Cyclosporine A (CYA) belongs to calcineurin inhibitor family, which has the ability to selectively suppress T cells. Owing to its immune-modulatory effects, it had been in use for graft vs host diseases and organ transplant rejection for many years, but in dermatology, it was first approved for use in 1997 in the treatment of psoriasis. Other off-label indications for skin diseases include atopic dermatitis, chronic spontaneous urticaria, lichen planus, pyoderma gangrenosum, alopecia areata, granuloma annulare, and several others. A thorough search of Medline-PubMed database, Google Scholar, and Uptodate was performed for evidence-based and peer-reviewed information. We have summarized the use of cyclosporine in dermatological diseases with respect to its, dosage, safety considerations, and monitoring guidelines. Furthermore, brief overview of its pharmacology, drug interactions, use in pregnancy, and lactation has been discussed. Despite of its common adverse effects like nephrotoxicity and hypertension, cyclosporine offers good safety profile when used in skin diseases. Decision to start cyclosporine therapy is individualized and it should be based on analysis of risk vs benefit. Nevertheless, CYA is preferred over other immunosuppressants in dermatology because of early therapeutic response and less myelosupression. This article offers concise but detailed summary of this beneficial immune-suppressive agent in skin diseases. K E Y W O R D S cyclosporine, dermatology, practical use 1 | INTRODUCTION Cyclosporine A (CYA) is a lipophilic cyclic polypeptide produced by fungal species (Tolypocladium inflatum), which was initially identified as antifungal agent but later found to have immense immunosuppressive properties. It inhibits T-cell activation by selectively inhibiting calcineurin phosphatase, thus suppressing production of IL-2. It has been in clinical practice for more than 30 years. It was initially employed primarily for the treatment of graft vs host diseases and organ transplant rejection but in 1997 U.S. Food and Drug Administration (FDA) approved its use in dermatology for the treatment of psoriasis. 1 Other off-label indications for skin diseases include atopic dermatitis, chronic spontaneous urticaria (CSU), lichen planus (LP), pyoderma gangrenosum (PG), alopecia areata (AA), and granuloma annulare. We used various search engines to get updated information, namely, Medline-PubMed database, Google Scholar, and Uptodate for evidence-based and peer-reviewed publications till April 2020. Systematic reviews, randomized controlled trials, and observational studies were screened and short-listed for critical evaluation of evidence. 2 | PHARMACOLOGY CYA binds with cytoplasmic proteins known as cyclophilins and this complex competitively binds and inhibits calcineurin. This leads to reduction in transcription of interleukin (IL)-2, tumor necrosis factor alpha (TNF-α), IL-3 and IL-4, interferon gamma, and granulocyte-Authors declare that the contents of this article are their own original and unpublished work.